Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition.

@article{Zhang2002PharmacokineticsOP,
  title={Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition.},
  author={Xiaoping Zhang and Keith A Nieforth and JonasW. B. Lang and R{\'e}gine Rouzier-Panis and J. Reynes and Albert E. Dorr and Stanley J. Kolis and Mark R. Stiles and Tosca Kinchelow and Indravadan H. Patel},
  journal={Clinical pharmacology and therapeutics},
  year={2002},
  volume={72 1},
  pages={
          10-9
        }
}
OBJECTIVE Enfuvirtide (T-20) is the first of a novel class of human immunodeficiency virus (HIV) drugs that block gp41-mediated viral fusion to host cells. The objectives of this study were to develop a structural pharmacokinetic model that would adequately characterize the absorption and disposition of enfuvirtide pharmacokinetics after both intravenous and subcutaneous administration and to evaluate the dose proportionality of enfuvirtide pharmacokinetic parameters at a subcutaneous dose… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Similar Papers

Loading similar papers…